All conditions

Rheumatoid Arthritis

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

2692
Trials on record
188
Recruiting now
13
Australian sites
13
Phase 3 trials
15
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Rheumatoid Arthritis →

Get alerts when Rheumatoid Arthritis trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a condition where the body's immune system mistakenly attacks its own joints, causing inflammation, pain, stiffness, and swelling. Unlike the wear-and-tear type of arthritis that often comes with ageing, RA is an autoimmune condition, which means the immune system is not working as it should. It most commonly affects the hands, wrists, and feet, though it can involve other joints and sometimes other parts of the body too. Symptoms can come and go, with periods of flare-ups and quieter times in between.

RA is one of the most common autoimmune conditions in Australia, affecting around 2% of the population — roughly 456,000 Australians. It can develop at any age, including in younger adults, and is about three times more common in women than men. Receiving this diagnosis can feel overwhelming at first, and it is completely normal to have a lot of questions.

Treatment for RA in Australia is generally managed by a specialist called a rheumatologist, often working alongside your GP and other health professionals. The main goal of treatment is to reduce inflammation, relieve symptoms, and help protect the joints from further damage over time. Approaches typically include medications, physical activity, and support from allied health professionals such as physiotherapists and occupational therapists. Many people with RA are able to manage their symptoms effectively and maintain a good quality of life with the right support and care in place.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Rheumatoid Arthritis in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Rheumatoid Arthritis

15 medicines listed on the PBS for Rheumatoid Arthritis. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 15 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Abatacept Orencia ClickJect, Orencia Severe active rheumatoid arthritis AU$262.4 Authority required
Adalimumab Hadlima, Hyrimoz, Humira +1 more Severe active rheumatoid arthritis AU$444.17 Authority required
Baricitinib Olumiant Severe active rheumatoid arthritis AU$934 Authority required
Certolizumab pegol Cimzia Severe active rheumatoid arthritis AU$938.04 Authority required
Etanercept Enbrel, Brenzys Severe active rheumatoid arthritis AU$371.81 Authority required
Golimumab Simponi Severe active rheumatoid arthritis AU$939.99 Authority required
Infliximab Inflectra, Remsima SC Severe active rheumatoid arthritis AU$186.16 Authority required
Leflunomide Arava Severe active rheumatoid arthritis AU$10.15 Restricted benefit
Methotrexate Trexject Severe active rheumatoid arthritis AU$18 Streamlined authority
Tocilizumab Actemra Subcutaneous Injection, Actemra ACTPen, Actemra Severe active rheumatoid arthritis AU$80.97 Authority required
Tofacitinib Xeljanz Severe active rheumatoid arthritis AU$1037.85 Authority required
Upadacitinib Rinvoq Severe active rheumatoid arthritis AU$1092.47 Authority required
Celecoxib Celebrex Rheumatoid arthritis AU$4 Restricted benefit
Infliximab Remicade Rheumatoid arthritis AU$186.16 Authority required
Meloxicam CIPLA MELOXICAM 7.5, CIPLA MELOXICAM 15, Moxicam Rheumatoid arthritis AU$3.1 Restricted benefit
Ciclosporin Neoral 10, Neoral, Neoral 25 +2 more rheumatoid arthritis Severe active AU$22.04 Streamlined authority

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Rheumatoid Arthritis currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Rheumatoid Arthritis.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Rheumatoid Arthritis by country. Australia is highlighted.

Showing the top 10 of 71 countries with trial sites.

Clinical trials for Rheumatoid Arthritis

Showing 211 of 211 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00124449 · Bristol-Myers Squibb Phase 2 · 10 countries Completed
Completed Phase 2 Est. completion 1 May 2007
🇦🇺 AU🇧🇪 BE🇫🇷 FR🇩🇪 DE🇮🇹 IT🇲🇽 MX Puerto Rico🇪🇸 ES +2 more

Who might be able to join this trial: - You have been diagnosed with a type of early, not fully defined joint inflammation called "undifferentiated arthritis." - You have visible joint swelling (synovitis) in two or more joints. - You meet at least one, but no more than three, of the standard medical checklist items us...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00264537 · Centocor, Inc. Phase 3 · 21 countries Completed
Completed Phase 3 Est. completion 1 April 2008
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇱 CL🇭🇺 HU🇮🇳 IN +13 more

**Who might be able to join this trial:** - You have been diagnosed with rheumatoid arthritis (RA) for at least 3 months before starting the study - You have never taken methotrexate (MTX) before, or have taken no more than 3 weekly doses of it for RA at any time - Your RA is currently active, meaning you have at leas...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00264550 · Centocor, Inc. Phase 3 · 12 countries Completed
Completed Phase 3 Est. completion 1 September 2007
🇦🇷 AR🇦🇺 AU🇨🇦 CA🇨🇱 CL🇩🇪 DE🇭🇺 HU🇲🇽 MX🇳🇿 NZ +4 more

**Who might be able to join this trial:** - You have been diagnosed with rheumatoid arthritis (RA) for at least 3 months before the screening visit - You have been taking methotrexate (a common RA medication) at a dose of at least 15 mg per week for at least 3 months, and your dose has stayed the same for at least 4 we...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00413699 · Pfizer Phase 3 · 43 countries Completed
Completed Phase 3 Est. completion 30 November 2016
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE Bosnia and Herzegovina🇧🇷 BR🇧🇬 BG🇨🇦 CA +35 more

**Who might be able to join this trial:** - You must have already taken part in a separate, randomised clinical trial of CP-690,550 (also called tofacitinib) for rheumatoid arthritis that qualifies you for this study - If you are currently taking part in a specific related study (A3921024), you must have been taking CP...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00422383 · Hoffmann-La Roche Phase 3 · 18 countries Completed
Completed Phase 3 Est. completion 1 March 2013
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇮 FI🇫🇷 FR🇩🇪 DE +10 more

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with rheumatoid arthritis (RA) for at least 6 months - You are receiving treatment as an outpatient (not staying in hospital) - You have been taking methotrexate for at least 12 weeks, have tolerated it, and have been...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00547521 · Bristol-Myers Squibb Phase 3 · 4 countries Completed
Completed Phase 3 Est. completion 1 December 2008
🇦🇺 AU🇲🇽 MX🇿🇦 ZA🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Rheumatoid Arthritis by a doctor - You rate your overall disease condition as at least 20 out of 100 on a simple sliding scale measurement - You are willing and able to stop taking all biological treatments and most other arthritis medications, except...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00837811 · Eli Lilly and Company Phase 2 · 14 countries Completed
Completed Phase 2 Est. completion 1 January 2011
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇩🇪 DE🇭🇺 HU +6 more

**Who might be able to join this trial:** - You have signed and given written consent to take part in the study. - Women must not be pregnant, breastfeeding, or likely to become pregnant during the study. - You must have previously taken part in one of two specific earlier studies (called NCT00689728 or NCT00785928)....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00960440 · Pfizer Phase 3 · 14 countries Completed
Completed Phase 3 Est. completion 1 March 2011
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇪 IE +6 more

Who might be able to join this trial: - You are an adult who has been diagnosed with moderate to severe rheumatoid arthritis - You are taking methotrexate at a steady, unchanged dose - You have tried TNF inhibitor medications (a type of treatment that targets inflammation) but they have not worked well enough for you...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00973479 · Centocor, Inc. Phase 3 · 13 countries Completed
Completed Phase 3 Est. completion 1 March 2011
🇦🇷 AR🇦🇺 AU🇨🇴 CO🇭🇺 HU🇱🇹 LT🇲🇾 MY🇲🇽 MX🇳🇿 NZ +5 more

Who might be able to join this trial: - You have been diagnosed with rheumatoid arthritis (a condition where the immune system attacks the joints) for at least 3 months before the screening visit. - You have been taking methotrexate (a common arthritis medication) at a dose of at least 15 mg per week for at least 3 mon...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01007435 · Hoffmann-La Roche Phase 3 · 36 countries Completed
Completed Phase 3 Est. completion 31 May 2012
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇴 CO🇩🇰 DK +28 more

Who might be able to join this trial: - You must be 18 years of age or older. - You must have been diagnosed with rheumatoid arthritis for 2 years or less. - Your rheumatoid arthritis must be considered moderately to highly active, based on a standard disease activity measurement called the DAS28 score (confirm with tr...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01142726 · Bristol-Myers Squibb Phase 3 · 15 countries Completed
Completed Phase 3 Est. completion 1 September 2013
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇮 FI🇫🇷 FR🇩🇪 DE🇮🇹 IT +7 more

Who might be able to join this trial: - You have active joint swelling and inflammation in at least 2 joints (one of which must be a small joint, such as in the hand or foot), and this has been present for at least 8 weeks before your initial assessment - Your joint symptoms started no more than 2 years before your ini...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01194414 · Hoffmann-La Roche Phase 3 · 26 countries Completed
Completed Phase 3 Est. completion 1 January 2012
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇴 CO🇫🇷 FR🇩🇪 DE +18 more

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with rheumatoid arthritis (RA) for at least 6 months, based on recognised medical guidelines - You have at least 4 swollen joints and at least 4 tender joints at the time of your first assessment and at the start of t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01197521 · AstraZeneca Phase 3 · 17 countries Completed
Completed Phase 3 Est. completion 1 November 2012
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇱 CL🇪🇪 EE🇫🇷 FR +9 more

**Who might be able to join this trial:** - You have been diagnosed with rheumatoid arthritis (RA), and you were at least 16 years old when you were diagnosed - You are currently taking the medication methotrexate - You have 6 or more swollen joints AND 6 or more tender or painful joints, plus at least one of two spec...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01519791 · UCB Pharma SA Phase 3 · 22 countries Completed
Completed Phase 3 Est. completion 1 July 2014
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇴 CO🇨🇿 CZ🇫🇷 FR +14 more

**Who might be able to join this trial:** - You were diagnosed with Rheumatoid Arthritis (RA) as an adult, and your diagnosis was made less than 1 year ago - Your blood tests show positive results for certain markers linked to RA (called Rheumatoid Factor and/or anti-CCP antibodies) - Your RA is currently active (meani...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01721044 · Eli Lilly and Company Phase 3 · 22 countries Completed
Completed Phase 3 Est. completion 1 June 2014
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE +14 more

Who might be able to join this trial: - People who have been diagnosed with adult-onset Rheumatoid Arthritis (RA) according to the 2010 classification guidelines set by major rheumatology organisations - People whose RA is moderately to severely active, meaning at least 6 out of 68 joints are tender and at least 6 out...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01856309 · Janssen Research & Development, LLC Phase 3 · 29 countries Completed
Completed Phase 3 Est. completion 30 April 2018
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇬 BG🇨🇦 CA🇨🇱 CL🇨🇴 CO +21 more

Who might be able to join this trial: - You must have already completed participation in one of two specific related studies (called CNTO136ARA3002 or CNTO136ARA3003). - You must be willing to sign a consent form showing you understand what the study involves and agree to take part. - You must be willing to sign a sepa...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02222493 · Pfizer Phase 3 · 28 countries Completed
Completed Phase 3 Est. completion 29 June 2016
🇦🇺 AU Bosnia and Herzegovina🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇬🇪 GE🇩🇪 DE +20 more

**Who might be able to join this trial:** - You have been diagnosed with rheumatoid arthritis (a condition causing joint inflammation) for at least 4 months, based on specific medical guidelines - You have at least 6 painful and 6 swollen joints (out of a standard set checked by a doctor) at two separate check-in appoi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02675426 · AbbVie Phase 3 · 38 countries Completed
Completed Phase 3 Est. completion 21 April 2017
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE Bosnia and Herzegovina🇧🇬 BG🇨🇦 CA🇭🇷 HR +30 more

Who might be able to join this trial: - You are a man or woman aged 18 or older. - You have been diagnosed with rheumatoid arthritis (RA) for at least 3 months. - You have been taking a standard RA medication (such as methotrexate, sulfasalazine, hydroxychloroquine, chloroquine, or leflunomide) for at least 3 months, a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02706847 · AbbVie Phase 3 · 27 countries Completed
Completed Phase 3 Est. completion 3 April 2017
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇪🇪 EE🇫🇮 FI🇫🇷 FR +19 more

Who might be able to join this trial: - You have been diagnosed with rheumatoid arthritis (RA) for at least 3 months. - You have been treated with at least one biological medication (a type of advanced drug for RA) for at least 3 months, but your RA is still active, or you had to stop taking it because of side effects...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02706951 · AbbVie Phase 3 · 25 countries Completed
Completed Phase 3 Est. completion 2 October 2017
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇬 BG🇨🇱 CL🇨🇿 CZ🇪🇪 EE +17 more

**Who might be able to join this trial:** - You have been diagnosed with rheumatoid arthritis (RA) for at least 3 months. - You have been taking methotrexate (MTX) pills or injections for at least 3 months, and your dose has stayed the same for at least 4 weeks before starting the trial. - You have stopped taking all o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02808871 · Brigham and Women's Hospital Phase 2 · 4 countries Completed
Completed Phase 2 Est. completion 7 April 2021
🇦🇺 AU🇨🇦 CA🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 85 years old at the time of screening - People who have been diagnosed with rheumatoid arthritis (RA) according to recognised 2010 diagnostic standards, with no signs of another condition that could be causing their lung disease - People who have been diagn...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02889796 · Gilead Sciences Phase 3 · 30 countries Completed
Completed Phase 3 Est. completion 4 July 2018
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇩🇪 DE Hong Kong +22 more

Who might be able to join this trial: - You have been diagnosed with rheumatoid arthritis (a condition where the immune system attacks the joints) based on recognised medical guidelines. - Your rheumatoid arthritis is rated as functional class I, II, or III, meaning you have some ability to carry out daily activities (...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02469662 · Zimmer Biomet Not Applicable · 8 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2035
🇦🇺 AU🇫🇮 FI🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who have signed a consent form that has been approved by an ethics review board. - People who have been identified as a candidate for a first-time or repeat total elbow replacement surgery, due to at least one of the followin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05638854 · Zenas BioPharma (USA), LLC Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 July 2025
🇦🇺 AU🇳🇿 NZ

**Who might be able to join this trial:** *Part A – Healthy Volunteers (single dose portion of the trial):* - Adults aged 18 to 55 who are generally in good health - People who meet minimum weight requirements (at least 50 kg for men, at least 45 kg for women) and whose body weight falls within a healthy range relativ...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06108934 · Stryker Australia Pty Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇦🇺 AU

Who might be able to join this trial: - People who have signed the study's consent form, which has been approved by a Human Research Ethics Committee (HREC) - People diagnosed with a non-inflammatory degenerative joint condition such as osteoarthritis or avascular necrosis (bone tissue death due to reduced blood supply...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06747949 · Amgen Phase 3 · 26 countries Recruiting
Recruiting Phase 3 Est. completion 11 December 2029
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇭🇷 HR🇫🇷 FR +18 more

**Who might be able to join this trial:** - People who gave their informed consent before any study activities began - People who previously took part in one of the related Phase 3 Sjögren's syndrome studies (HZNP-DAZ-301 or HZNP-DAZ-303), received the study drug or placebo, and completed that study up to the Week 48...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06917742 · Capstan Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2027
🇦🇺 AU

**Who might be able to join this trial:** - You are generally healthy, as confirmed by a doctor reviewing your medical history, a physical check-up, and lab tests done during the screening process. - You are willing and able to attend all required study visits and follow the study's rules. **If you have Rheumatoid Ar...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07017686 · The Bionics Institute of Australia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇦🇺 AU

**Who might be able to join this trial:** - You are between 18 and 75 years old (male or female) - You have been diagnosed with rheumatoid arthritis (RA) that started when you were 18 or older, and a specific blood test for RA (RF, CCP, or ACPA) has come back positive - Your RA is moderately to severely active, with a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT07118241 · Lubris Bio Pty Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 July 2026
🇦🇺 AU

**Who might be able to join this trial:** - People who are able to understand the study and sign and date a consent form - People who are between 18 and 75 years old at the time of giving consent - People who have been diagnosed with Sjögren's syndrome (SS) for at least 3 months before joining the study - People who h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07201558 · AstraZeneca Phase 1 · 10 countries Recruiting
Recruiting Phase 1 Est. completion 27 June 2028
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇳 CN🇩🇪 DE🇪🇸 ES🇹🇼 TW🇺🇦 UA +2 more

**Who might be able to join this trial:** - People aged 18 to 65 years old (or the legal age of consent in the country where the trial is taking place) at the time of signing the consent form. - People diagnosed with Rheumatoid Arthritis (RA) according to recognised international classification standards (2010 EULAR/A...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07207954 · Lifordi Immunotherapeutics, Inc. Phase 1 · 5 countries Recruiting
Recruiting Phase 1 Est. completion 16 July 2027
🇦🇺 AU🇬🇪 GE Moldova🇵🇱 PL🇺🇦 UA

Who might be able to join this trial: **Healthy participants:** - People aged 18 to 55 years old - People with a body mass index (a measure of body weight relative to height) between 18 and 32 - People who a doctor determines to be in generally good health based on a physical check-up, medical history, vital signs, an...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07234773 · Kali Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 February 2027
🇦🇺 AU

**Who might be able to join this trial:** - People aged 18 to 75 years old - People who have been diagnosed with rheumatoid arthritis (RA) as an adult, for at least 6 months - People whose RA is considered moderately to severely active - People whose RA has not responded well enough to previous treatment, as defined by...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07284797 · Xencor, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2028
🇦🇺 AU

Who might be able to join this trial: - Adults who are in good general health (for the healthy participant group) - Adults who have been diagnosed with idiopathic inflammatory myopathy (a condition where the immune system attacks the muscles), based on specific 2017 classification criteria used by rheumatology organis...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07295847 · AstraZeneca Phase 1 · 5 countries Recruiting
Recruiting Phase 1 Est. completion 22 February 2028
🇦🇺 AU🇩🇪 DE🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are able to understand and sign a consent form agreeing to take part - Your overall physical health and body function are considered adequate at the start of the study - You are willing and able to stop taking certain medications for a set period of time before the study...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07363590 · Merck Sharp & Dohme LLC Phase 1 · 10 countries Recruiting
Recruiting Phase 1 Est. completion 16 July 2029
🇦🇺 AU🇧🇪 BE🇨🇳 CN🇨🇴 CO🇬🇪 GE🇮🇹 IT🇯🇵 JP Moldova +2 more

**Who might be able to join this trial:** - People whose body mass index (a measure of body weight relative to height) falls between 18 and 32 - People who have been diagnosed with Systemic Lupus Erythematosus (SLE) — a chronic immune system disease — for at least 6 months, and whose diagnosis meets a specific set of...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00427934 · Pfizer Phase 2 · 9 countries Terminated
Terminated Phase 2 Est. completion 1 October 2008
🇦🇺 AU🇩🇪 DE🇮🇳 IN🇮🇹 IT🇲🇽 MX🇵🇹 PT🇪🇸 ES🇺🇦 UA +1 more

**Who might be able to join this trial:** - You must be at the legal age of consent in your country - You must have been diagnosed with active rheumatoid arthritis based on a specific set of recognized medical guidelines (the ACR 1987 Revised Criteria), with a minimum level of disease activity required to participate -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00512239 · Gilles Boire Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇨🇦 CA

Who might be able to join this trial: - You have been diagnosed with early rheumatoid arthritis (a condition where the immune system attacks the joints, causing pain and swelling) - You have been diagnosed with early inflammatory arthritis (joint inflammation that has been present for a short time) Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00748254 · University of Michigan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older. - People who have had rheumatoid arthritis for more than 2 years and whose rheumatologist has referred them to this study. - People with a known history of rheumatoid arthritis who are able to participate as a healthy volunteer. Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01425892 · National Institute of Dental and Craniofacial Research (NIDCR) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - People who are able to read and sign a consent form agreeing to take part in the study - People who have been diagnosed with Sjögren's disease (a condition that affects moisture-producing glands) based on established medical classification guidelines - People who meet most of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02143986 · Brugmann University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇧🇪 BE

"Who might be able to join this trial: - People who are suspected of having sepsis, macrophage activation syndrome, Still's disease, or high ferritin levels caused by conditions such as cancer or liver cell damage. Who may not be able to join: - People whose ferritin levels are within the normal range. Important: Alw...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02327884 · National Institute of Dental and Craniofacial Research (NIDCR) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2032
🇺🇸 US

Who might be able to join this trial: - People older than 4 years of age who have, or are suspected of having, a disease or condition affecting the salivary glands, or who are a family member of someone with such a condition. - People aged 18 or older who have active hepatitis (with or without dry mouth or dry eye symp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02714634 · University Hospital, Strasbourg, France Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 March 2029
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with rheumatoid arthritis (RA) based on recognised international medical guidelines (EULAR/ACR 2010 criteria) - People whose RA is considered moderately to highly active, based on a standard disease activity score (DAS28-CRP above 3.2) - People...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT02748408 · Medacta International SA Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 July 2032
🇦🇹 AT🇮🇹 IT🇨🇭 CH🇬🇧 GB

**Who might be able to join this trial:** - People who have a severely painful or disabling hip joint caused by osteoarthritis, injury-related arthritis, a hip condition present from development (developmental dysplasia), or bone tissue death in the hip (avascular necrosis of the femoral head). - People who are between...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03003572 · Centre Hospitalier Universitaire de Saint Etienne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with primary Sjögren's syndrome based on a specific set of internationally recognised diagnostic guidelines (called the American-European Consensus Criteria) - People who have been informed about the study and have signed the consent form agreei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03048201 · Limacorporate S.p.a Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2030
🇺🇸 US

**Who might be able to join this trial:** - You are male or female, of any race, and your doctor has recommended a total knee replacement - You are over 22 years old and your bones have finished growing - You have a knee condition such as osteoarthritis, arthritis caused by a previous injury, inflammatory arthritis (s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03192267 · University of Nebraska Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2029
🇺🇸 US

Who might be able to join this trial: - People between 19 and 90 years of age. - People who are able to give their informed consent to participate. - People who have been diagnosed with rheumatoid arthritis (RA) by a rheumatologist using a specific set of medical guidelines (the 2010 American College of Rheumatology cr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03414502 · University of Nebraska Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with rheumatoid arthritis (RA) meeting at least 4 out of 7 specific criteria set by the American College of Rheumatology. - You had morning stiffness lasting at least 1 hour, for at least 6 weeks. - You have had swelling in 3 or more joints for at lea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03510442 · National Institute of Arthritis and Musculoskeletal and Skin Diseases... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2050
🇺🇸 US

Who might be able to join this trial: - Children under 16 who meet the established medical classification criteria (called ILAR criteria) for a condition called systemic juvenile idiopathic arthritis (sJIA), which is a type of childhood arthritis with fever and inflammation - People aged 16 or older who previously met...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03728478 · Istituto Giannina Gaslini Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 28 February 2025
🇮🇹 IT

Who might be able to join this trial: - Children aged 2 to 17 years who have been recently diagnosed with a specific type of juvenile idiopathic arthritis (JIA) — either the type affecting a few joints (oligoarthritis) or the type affecting many joints without a certain blood marker called rheumatoid factor (RF-negativ...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03770702 · Sherief Abd-Elsalam Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2025
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with rheumatoid arthritis. Who may not be able to join: - People who are currently pregnant or breastfeeding. - People who have liver or kidney problems. Important: Always verify eligibility with the trial site directly before applying.

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03770923 · Sherief Abd-Elsalam Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2026
🇪🇬 EG

Who might be able to join this trial: - You have been diagnosed with rheumatoid arthritis Who may not be able to join: - You have a liver disease or condition - You have a kidney (renal) disease or condition Important: Always verify eligibility with the trial site directly before applying.

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03938701 · University Medical Center Groningen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with either Inflammatory Bowel Disease (IBD) or Rheumatic Disease (RD) - Your disease is currently active — for IBD, this means your bowel disease is at least mildly active (confirmed by a doctor's assessment or a stool test result above a certain lev...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04238143 · Healeon Medical Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People with documented osteoarthritis or inflammatory/degenerative changes in the knee, hip, shoulder, Achilles tendon, sacroiliac joint, wrist, hand, foot, ankle, or plantar fascia (the tissue on the bottom of the foot) - People without systemic (whole-body) disorders that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04247672 · Spaarne Gasthuis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 January 2024
🇳🇱 NL

**Who might be able to join this trial:** - People who have severe knee osteoarthritis that has reached the stage where a knee replacement is needed - People for whom a specific knee replacement system (called the ATTUNE total knee system) has been chosen as part of their normal medical care - People who are willing an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04292067 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇫🇷 FR

**Who might be able to join this trial:** **For patients with a diagnosed condition:** - People aged 18 or older - People who have been diagnosed with spondyloarthritis (a type of inflammatory joint disease) or rheumatoid arthritis, based on recognised medical classification systems - People who are covered by a Frenc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04692493 · University of Alabama at Birmingham Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 31 May 2029
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who have active, disabling rheumatoid arthritis (a disease score meeting specific thresholds) even after trying a TNF-inhibitor biologic medication, or who had to stop that medication because of side effects or intolerance - People who, if taking steroid medications (...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04748809 · University of California, San Diego Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a condition where disease activity is low or moderate (based on a scoring system called the Clinical Disease Activity Index, with a score of 22 or below) - People whose condition and treatment have been stable, with no changes in the past 3...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04751396 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 February 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with melanoma - You have also been diagnosed with a pre-existing autoimmune condition, which must be one of the following: - **Inflammatory bowel disease** (Crohn's disease or ulcerative colitis, diagnosed by a gastroenterologist, with ulcerative co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04848870 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 January 2032
🇫🇷 FR

"Who might be able to join this trial: - You have been diagnosed with Sjögren Syndrome - You are over 18 years old - You are covered by a social security or health insurance system (not including AME) (confirm with trial site) - You can read and understand French well enough to follow the study information - You agree...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04955899 · Galvani Bioelectronics Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2029
🇳🇱 NL🇬🇧 GB

**Who might be able to join this trial:** - You were diagnosed with rheumatoid arthritis (RA) as an adult, and have had it for at least six months - You are between 22 and 75 years old (male or female) - Your rheumatoid arthritis is currently active (causing symptoms) - Your RA has not responded well enough to at least...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04981145 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with primary Sjögren's syndrome (pSS) based on the 2016 international classification criteria for this condition. - People who experience symptoms of dry mouth and dry eyes. - People whose blood test at the screening stage shows a positive resu...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04985435 · R.Bos Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 September 2025
🇳🇱 NL

**Who might be able to join this trial:** - You are 18 years of age or older, male or female. - You are willing and able to sign a consent form agreeing to take part in the study. - You have a good enough understanding of the Dutch language to follow the study requirements. - You have been diagnosed with rheumatoid art...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05003310 · Galvani Bioelectronics Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇳🇱 NL🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with rheumatoid arthritis (RA) for at least six months, based on recognised 2010 diagnostic guidelines - People aged between 22 and 75 years, of any gender - People whose rheumatoid arthritis is currently active (meaning symptoms are present and ong...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05003934 · The Foundation for Orthopaedics and Regenerative Medicine Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 September 2026
Antigua and Barbuda🇦🇷 AR

Who might be able to join this trial: - You have been diagnosed with Rheumatoid Arthritis - You are willing and able to understand and sign a written consent form agreeing to take part Who may not be able to join: - You currently have an active infection - You currently have active cancer - You have long-term failure...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05062421 · Fundación Pública Andaluza para la gestión de la Investigación en Sevi... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇪🇸 ES

Who might be able to join this trial: - You must be 18 years old or older. - You must have been diagnosed with Adult Rheumatoid Arthritis based on specific 2010 medical guidelines (confirm with trial site). - You must have already received at least one dose of the medications being studied in this trial. - You must be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05092984 · University Hospital, Strasbourg, France Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2026
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been diagnosed with rheumatoid arthritis (RA) according to standard 2010 classification guidelines - People whose RA is currently active, based on a disease activity score called DAS28-CRP being 3.2 or higher - People who have not re...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05197530 · University of Rochester Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** **For people with early rheumatoid arthritis (RA):** - People who are able to give written consent to participate - People aged 18 or older - People who have been diagnosed with rheumatoid arthritis according to 2010 ACR criteria, with a disease activity score (DAS28-CRP) abov...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05264025 · October 6 University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇪🇬 EG

Who might be able to join this trial: - People diagnosed with moderate to severe rheumatoid arthritis, based on a standard disease activity score (DAS-28 score above 3.2) - People aged between 18 and 60 years old whose arthritis is currently active, as confirmed by an experienced arthritis specialist - People currently...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05278520 · University of Turku Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇫🇮 FI

**Who might be able to join this trial:** **Main study – Case group:** - Adults who have osteoarthritis in the hip joint and are scheduled for a planned total hip replacement surgery **Main study – Control group:** - Adults who do not have arthritis and are having an emergency total hip replacement surgery due to a t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05302934 · Aesculap AG Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇩🇪 DE🇬🇧 GB

Who might be able to join this trial: - People who are having a total knee replacement surgery using a B. Braun knee implant system - People who have signed a written consent form agreeing to take part - People who are willing and able to use a sensor device called the "BPMpathway" - People who are willing and able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05305066 · Marie Hudson, MD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇦 CA

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with rheumatoid arthritis (RA) based on recognized medical guidelines - For one part of the study (Sub-study 1): Your standard first-line arthritis medications have not worked well enough, and your doctor considers yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05365009 · EPIMAR registry Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2023
🇦🇷 AR

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with interstitial lung disease (a condition causing scarring or inflammation in the lungs) within the last 5 years, as confirmed by a team that includes at least one lung specialist and one joint/autoim...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05413759 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with rheumatoid arthritis (RA) - You are 18 years old or older (male or female) - You are either staying in hospital or attending an outpatient appointment in a rheumatology department, and you return home after your visit - You are currently taking or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05428488 · University Hospital, Montpellier Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 November 2026
🇫🇷 FR Monaco

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with rheumatoid arthritis according to the 2010 ACR-EULAR classification criteria - People who test positive for ACPA (a specific antibody associated with rheumatoid arthritis) - People who have been taking methotrexat...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05533372 · ILAb Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2025
🇺🇸 US

**Who might be able to join this trial:** - People who are male or female, aged 18 to 55 (for the healthy volunteer part) or 18 to 70 (for the rheumatoid arthritis patient part), at the time of screening. - People with a body weight of at least 50 kg at screening. - People whose body mass index (a measure of weight re...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05540938 · China-Japan Friendship Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been diagnosed with rheumatoid arthritis according to recognised international diagnostic standards (1987 ACR or 2010 ACR/EULAR criteria) - People whose rheumatoid arthritis also meets a specific Traditional Chinese M...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05619588 · Exactech Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been recommended for a total ankle replacement surgery - People whose bones have finished growing (skeletally mature) - People who are mentally able to complete follow-up questionnaires and forms - People who are able to attend follow-up appointments for up to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05626348 · Qilu Hospital of Shandong University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Rheumatoid Arthritis (RA) using recognised medical guidelines, AND you have problems with your knee function. - You meet the 1987 RA classification by having at least 4 of these 7 signs: morning stiffness lasting at least 1 hour (for 6+ weeks); 3...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05691868 · Exactech Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇪🇸 ES🇨🇭 CH

**Who might be able to join this trial:** - Your doctor has recommended you for a total ankle replacement surgery - You are at least 21 years old - You are likely to be available for follow-up appointments for up to 10 years after surgery - You are willing to attend all required appointments before and after the proced...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05697159 · NHS Greater Glasgow and Clyde Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2025
🇬🇧 GB

Who might be able to join this trial: - People aged 18 to 74 years old with moderate to severe active rheumatoid arthritis, for whom a doctor has prescribed the medication filgotinib in line with the approved product guidelines. - People who are right-handed (this requirement helps keep brain imaging results consistent...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05717179 · Italian Society for Rheumatology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with rheumatoid arthritis (RA) based on standard 2010 classification criteria - People aged 18 to 84 years - People whose RA is currently moderately or highly active, based on a standard disease activity score (called CDAI, scored above 10) - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05760898 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older - You have high blood pressure that is not well controlled - You have been diagnosed with rheumatoid arthritis - You receive both your general (primary) care and your rheumatology (joint/arthritis specialist) care through the Duke Health System Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05782335 · Hospital for Special Surgery, New York Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older and have been diagnosed with rheumatoid arthritis (RA) - You are currently taking a medication called methotrexate (with or without other similar RA medications) at a steady dose for at least 4 weeks, and you are either about to start a drug cal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05790356 · London Health Sciences Centre Research Institute OR Lawson Research In... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with rheumatoid arthritis (RA) according to recognised international diagnostic guidelines - People who have tested positive for certain RA-related antibodies (known as ACPA and/or rheumatoid factor) found in blo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05926622 · Medacta International SA Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2032
🇫🇷 FR

Who might be able to join this trial: - People who are older than 18 years of age - People who have been diagnosed with one of the following shoulder conditions: primary osteoarthritis, secondary osteoarthritis, cuff tear arthropathy (a damaged or insufficient rotator cuff), an acute fracture that occurred less than 21...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05927688 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are a man or woman aged 18 or older - You have been diagnosed with at least one of the following conditions: Rheumatoid Arthritis, Gout, Systemic Lupus Erythematosus, or Sjögren's Syndrome (diagnosed using specific standard medical guidelines — confirm with trial site) -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05955066 · Chinese University of Hong Kong Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 February 2026
Hong Kong

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with rheumatoid arthritis (RA) according to recognized medical guidelines - You have been taking the medication methotrexate for at least 12 weeks - Your rheumatoid arthritis is not well controlled, based on a specific di...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05961592 · Rise Therapeutics LLC Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 75 years old (inclusive). - People who are able to give written consent to participate. - Men or women (who are not breastfeeding or pregnant) who have active rheumatoid arthritis (RA), confirmed using recognised international classification criteria. - Peo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05966519 · Zimmer Biomet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇯🇵 JP

**Who might be able to join this trial:** - People aged 20 years or older - People whose bones have finished growing and reached full maturity - People for whom a decision to have a total knee replacement using the ROSA Knee System has already been made independently, before being considered for the study - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05980442 · Aesculap AG Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇩🇪 DE

Here is the eligibility information for this clinical trial in plain language: **Who might be able to join this trial:** - People who need a total knee replacement surgery using a fixed type of knee implant - People who are willing and able to sign a written agreement to take part in the study **Who may not be able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06003283 · Universitaire Ziekenhuizen KU Leuven Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2027
🇧🇪 BE

**Who might be able to join this trial:** - You are willing and able to sign a consent form and take part in the study before anything begins. - You are 18 years old or older. - You can read and write in Dutch or French. - You have been diagnosed with rheumatoid arthritis based on recognised medical classification stan...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06072768 · VA Office of Research and Development Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2029
🇺🇸 US

**Who might be able to join this trial:** - People who can read and speak English, so they are able to give written consent and complete questionnaires - People who are willing to sign and date a consent form agreeing to take part - People who are willing and able to follow all study procedures for the full duration o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06129214 · Gangnam Severance Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 October 2025
🇰🇷 KR

**Who might be able to join this trial:** - People who are scheduled to have a total knee replacement surgery on both knees, using a specific type of implant called a "posterior stabilised" (PS) type **Who may not be able to join:** - People who are unable to attend follow-up appointments, including cases of patient d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06201416 · Sonoma Biotherapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2026
🇺🇸 US

Who might be able to join this trial: - Your Body Mass Index (BMI) must be below 35 (a measure of body weight relative to height) - You have been diagnosed with rheumatoid arthritis (RA) that started in adulthood and is considered moderate to severe - Your RA is currently moderately to severely active - You have tried...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06240299 · NHS Greater Glasgow and Clyde Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 January 2027
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with rheumatoid arthritis (RA) according to established international classification guidelines - People who also meet recognised criteria for chronic widespread pain (long-lasting pain spread across the body) - People whose rheumatoid arthriti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06246123 · Eisai Korea Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2027
🇰🇷 KR

**Who might be able to join this trial:** - You are currently being prescribed Jyseleca (filgotinib) tablets in South Korea, following the approved guidelines for its use there. - You have moderate to severe rheumatoid arthritis as an adult, and previous treatments (called DMARDs) have not worked well enough for you o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06301373 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with rheumatoid arthritis using recognised medical guidelines (from 1987 or 2010 standards) - Your rheumatoid arthritis is currently at a moderate or high level of activity - You have had a joint tissue sample (biopsy) taken, and the results showed a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06337786 · Henning Bliddal Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇩🇰 DK

Who might be able to join this trial: - You have been diagnosed with rheumatoid arthritis (RA) according to recognised medical guidelines - Your overall disease impact score (as rated by your doctor) is 40mm or higher on a standard scale - You are between 18 and 64 years old - You are motivated and willing to take part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06338735 · University of Pisa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

Who might be able to join this trial: - You must be an adult aged 18 or older - You must be suspected by a doctor of possibly having Sjögren's syndrome (a condition that affects the immune system and commonly causes dry eyes and dry mouth) - You must be willing to go through the full set of tests used to diagnose Sjögr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06392711 · University of Wisconsin, Madison Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with dry mouth, confirmed by a saliva flow test showing very low saliva production. - Your dry mouth is **not** caused by radiation therapy — it has a medical cause. - You are between 18 and 90 years old. - You are generally in good enough health to u...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06410833 · Peking Union Medical College Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Children and teenagers between 5 and 18 years old - People who have been diagnosed with Sjögren's syndrome (SS) based on recognised medical diagnostic guidelines - People whose Sjögren's syndrome has not responded well enough to treatment, meaning they have been on two or mo...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06428188 · Essen Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Doctors expect you to live for at least 3 more months. - You have a recurring or treatment-resistant autoimmune disease (such as lupus, rheumatoid arthritis, Sjögren's syndrome, or similar conditions) that has not responded to standard treatments or has no effective treatmen...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06492200 · Wuerzburg University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇩🇪 DE

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with Rheumatoid Arthritis based on the 2010 ACR (American College of Rheumatology) criteria - People who understand what the study involves and are willing to sign a written agreement to take part Who may n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06503237 · The First Affiliated Hospital of University of Science and Technology... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any gender, who are able to sign a consent form in person (or have a guardian sign on their behalf) before any screening begins. - People diagnosed with rheumatoid arthritis (RA) according to recognised 2010 diagnostic guidelines, whose condition has n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06527534 · Universita di Verona Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 15 July 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with Rheumatoid Arthritis (RA) according to specific medical guidelines, and whose disease is currently considered active based on standard scoring measurements - People who are older than 18 and younger than 65 years of age - People for whom a...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06527547 · Juan Jiao Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with rheumatoid arthritis according to a recognised set of medical guidelines (the 2010 ACR/EULAR criteria) - People who are experiencing poor sleep quality, based on a sleep questionnaire score above 7 (called the PSQI) - People whose rheumatoi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06528431 · Centre Hospitalier Universitaire de Saint Etienne Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 19 September 2026
🇫🇷 FR

Who might be able to join this trial: - People who are over 18 years of age - People who have been diagnosed with rheumatoid arthritis (RA) based on recognised international diagnostic guidelines (ACR/EULAR 2010 criteria) - People whose rheumatoid arthritis has been in remission (very low disease activity) for at least...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06536075 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇹🇼 TW

Who might be able to join this trial: - (Nomogram group) You do not have any dry mouth or dry eye symptoms. - (Sicca group) You are already receiving a salivary gland scan (a test called sialoscintigraphy) as part of your care. Who may not be able to join: - You are currently pregnant. - You are currently breastfeedin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06543667 · Iran University of Medical Sciences Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2026
Iran

Who might be able to join this trial: - People who experience burning, itching, or a sensation of something in their eye - People who have been assessed as having moderate or severe dry eye - People aged between 18 and 70 years Who may not be able to join: - People who have had eye surgery in the past - People who hav...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06546345 · Keri Medical SA Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older - You are planning to have a joint replacement surgery in one of the knuckle joints of your finger using a specific implant called KeriFlex® - You have been diagnosed with rheumatoid arthritis, osteoarthritis, or arthritis caused by a previous...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06567470 · Citryll BV Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇧🇪 BE🇩🇪 DE🇳🇱 NL🇵🇱 PL🇪🇸 ES

Who might be able to join this trial: - People diagnosed with rheumatoid arthritis (RA) for at least 3 months before the screening visit, based on recognised international classification guidelines - People aged between 18 and 85 years old - People whose RA is currently active, shown by a specific disease activity scor...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06572696 · Fatih Sultan Mehmet Training and Research Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 September 2024
Turkey (Türkiye)

Who might be able to join this trial: - People aged 18 to 75 who have been diagnosed with rheumatoid arthritis (RA) for at least 12 months, based on recognised international diagnostic standards - People who do not currently have any shoulder pain Who may not be able to join: - People with a suspected shoulder problem...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06574594 · Konkuk University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇰🇷 KR

Who might be able to join this trial: - People who have been diagnosed with rheumatoid arthritis according to the standard 2010 classification guidelines used by doctors - People who are older than 19 years of age - People who are currently taking the medication methotrexate - People who agree to receive the Shingrix v...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06579222 · Western University, Canada Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 June 2026
🇨🇦 CA

Who might be able to join this trial: - People who are patients at the Waterloo Rheumatology Community Clinic - People aged between 18 and 80 years old - People who have been diagnosed with rheumatoid arthritis - People who have at least a basic working ability to read and communicate in English - People who do not hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06596772 · mAbxience Research S.L. Phase 3 · 6 countries Recruiting
Recruiting Phase 3 Est. completion 1 October 2025
🇧🇬 BG🇬🇪 GE Moldova🇵🇱 PL🇷🇴 RO🇷🇸 RS

**Who might be able to join this trial:** - People who were diagnosed with rheumatoid arthritis (RA) at least 6 months ago but no more than 15 years ago, based on recognised medical criteria. - People who still have moderate to severe RA symptoms despite taking methotrexate (MTX), meaning they have 6 or more swollen j...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06599658 · McGill University Health Centre/Research Institute of the McGill Unive... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2027
🇨🇦 CA

**Who might be able to join this trial:** - Adults aged 18 or older - People who have received at least 3 doses of an mRNA COVID-19 vaccine as their primary vaccine series - People who have had a solid organ transplant (such as a kidney, liver, or heart) at least 3 months ago and are currently on standard anti-rejectio...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06613490 · The First Affiliated Hospital with Nanjing Medical University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 20 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part, can follow all the study steps, and have signed a consent form agreeing to participate. - You have been diagnosed with Rheumatoid Arthritis (RA) for at least 3 months, your RA is moderately to severely active, and previous treatments (such as di...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06631638 · DePuy Orthopaedics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - The hip replacement surgery being performed must follow the approved uses for all devices involved. - The person is having their first-ever uncemented hip replacement using specific implant components (EMPHASYS cup with a CORAIL, EMPHASYS, or ACTIS stem), performed through one of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06640309 · Ain Shams University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇪🇬 EG

Who might be able to join this trial: - Adults between 18 and 65 years of age. - People who have been diagnosed with established rheumatoid arthritis. - People whose rheumatoid arthritis is considered moderately to highly active, based on a specific scoring system that uses a blood marker called C-reactive protein (a s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06649136 · Medical University of Vienna Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 September 2026
🇦🇹 AT

Who might be able to join this trial: - Adults aged 18 or older who are able to understand and sign a consent form, and who can read and communicate well enough in the local language to follow the study steps - People who have been diagnosed with rheumatoid arthritis (RA) based on established international classificati...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06671054 · SynAct Pharma Aps Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇧🇬 BG🇩🇰 DK Moldova🇵🇱 PL🇺🇸 US

Who might be able to join this trial: - People who have signed and dated a consent form before any trial procedures begin. - People who have been officially diagnosed with rheumatoid arthritis (RA) according to recognised international classification standards. - People whose RA diagnosis was made no more than 6 months...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06693479 · Laval University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇨🇦 CA

**Who might be able to join this trial:** - Adults aged 18 or older who work full-time (at least 30 hours per week) - People experiencing shoulder problems related to their work, with symptoms severe enough to score at least 14 points on a standard shoulder disability questionnaire called the QuickDASH - People whose...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06712628 · AbbVie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed by your doctor with moderate to severe rheumatoid arthritis (RA) that is currently active, or you have had this diagnosis in the past. - Your doctor has already independently decided to prescribe you either Upadacitinib or a TNF inhibitor (a type of bi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06732674 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇳🇴 NO

**Who might be able to join this trial:** - You have been diagnosed with one of the following conditions: systemic sclerosis (scleroderma), rheumatoid arthritis, inflammatory muscle disease (including antisynthetase syndrome), mixed connective tissue disease, or Sjögren's disease, confirmed by standard medical criteria...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06753565 · German University in Cairo Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇪🇬 EG

**Who might be able to join this trial:** - You are between 18 and 60 years old - You have been diagnosed with rheumatoid arthritis (a condition where the immune system attacks the joints) for at least 6 months, based on recognized medical guidelines - You have been taking one or more standard arthritis medications (ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06758817 · Lisbon Academic Medical Center - Centro Académico de Medicina de Lisbo... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2025
🇵🇹 PT

**Who might be able to join this trial:** - You have been diagnosed with rheumatoid arthritis (RA) based on recognised medical guidelines - You are over 18 years old - You have had rheumatoid arthritis for more than 1 year - Your rheumatoid arthritis is currently active, meaning it is not well controlled (confirm with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06769386 · Kirsehir Ahi Evran Universitesi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 January 2026
Turkey (Türkiye)

Who might be able to join this trial: **Rheumatoid Arthritis Group:** - People who have been diagnosed with rheumatoid arthritis - People between 18 and 65 years of age - People who are willing to voluntarily take part in the study **Control Group (people without rheumatoid arthritis):** - People between 18 and 65 ye...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06771427 · Taipei Veterans General Hospital, Taiwan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇹🇼 TW

**Who might be able to join this trial:** *For people with Dry Eye Syndrome:* - People aged between 20 and 75 years - People whose Schirmer's test result (a test that measures tear production) shows less than 10 mm in 5 minutes, indicating low tear production *For people with Sjögren's Syndrome (an immune system cond...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06776965 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇫🇷 FR

Who might be able to join this trial: - People who are older than 18 years of age - People who have been diagnosed with a chronic rheumatic disease, specifically rheumatoid arthritis, spondyloarthritis, or osteoarthritis - People who are able to complete questionnaires Who may not be able to join: - People who are und...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06779123 · taVNS AB Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 October 2026
🇸🇪 SE

**Who might be able to join this trial:** - People who are over 18 years of age at the time of signing the consent form - People with active rheumatoid arthritis, measured by a disease activity score above 3.2, with at least 4 tender and 4 swollen joints (out of 28 joints assessed) - People whose rheumatoid arthritis d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06780293 · Taipei Veterans General Hospital, Taiwan Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2025
🇹🇼 TW

**Who might be able to join this trial:** **For the Dry Eye Syndrome group:** - People aged between 20 and 75 years - People whose Schirmer's test result (a test that measures how much moisture the eye produces) shows less than 10 mm of fluid in 5 minutes, indicating low tear production **For the Sjögren's Syndrome g...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06805448 · Rigshospitalet, Denmark Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇩🇰 DK

**Who might be able to join this trial:** - People who have been diagnosed with Sjögren's disease (a condition that affects moisture-producing glands) according to internationally recognised classification standards - People who are 18 years of age or older - People who have experienced persistent dry mouth for at leas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06841562 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with rheumatoid arthritis (RA) within the last 6 months and are not currently taking biologic (advanced injection or infusion) RA medications, though you may be taking one or more standard RA pills such as hydroxychloroquine, methotrexate, sulfasalazi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06857227 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who are able to understand and are willing to sign a consent form agreeing to take part - People of any gender are eligible - People aged 18 to 75 years old - People whose life expectancy is greater than 6 months - People who have been diagnosed with rheumatoid arthritis (...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06880653 · University of South Carolina Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed by a doctor with arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia - You are able to read and write in English Who may not be able to join: - You have a medical reason why you should not exercise (other than...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06887127 · Hangzhou Highlightll Pharmaceutical Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who completed the earlier related study (called TLL-018-301) within the past 3 months - People aged 18 to 75 years old at the time of giving consent - Women who could become pregnant must have a negative pregnancy test before joining and must not currently be pregnant or b...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06902519 · Gilead Sciences Phase 1 · 6 countries Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇬🇪 GE🇩🇪 DE Moldova🇵🇱 PL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who are not currently taking a biologic or targeted disease-modifying arthritis drug (called a b/tsDMARD), and who have stopped any such drug at least 4 weeks before the study starts (or at least 6 months before, for drugs that deplete B cells, such as rituximab). - P...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06906549 · University Hospital, Strasbourg, France Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 July 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with rheumatoid arthritis (RA) based on recognised medical classification guidelines - Your rheumatoid arthritis disease activity is at a moderate level or below, based on a standard scoring system called DAS28 (confi...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06913907 · Keio University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2027
🇯🇵 JP

**Who might be able to join this trial:** - People who have never previously been treated with methotrexate (MTX), by any method of taking it - People who are 18 years of age or older at the time of signing the consent form - People who have been diagnosed with rheumatoid arthritis according to the 2010 EULAR/ACR clas...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06915701 · University of Guadalajara Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 December 2026
🇲🇽 MX

**Who might be able to join this trial:** - People who are female - People who have been diagnosed with rheumatoid arthritis (RA) according to standard 2010 classification guidelines - People who have had rheumatoid arthritis for 2 years or less (considered "early" RA) - People currently being treated with certain stan...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06916806 · AstraZeneca Phase 1 · 10 countries Recruiting
Recruiting Phase 1 Est. completion 5 May 2027
🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE Hong Kong🇯🇵 JP🇳🇱 NL🇪🇸 ES +2 more

**Who might be able to join this trial:** **For people with Lupus (SLE):** - People aged 18 to 70 years old at the time of signing the consent form. - People who have been diagnosed with lupus (SLE) according to recognised international classification guidelines. - People who test positive for certain lupus-related an...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06933134 · University Hospital, Tours Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇫🇷 FR

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with rheumatoid arthritis based on the 2010 ACR/EULAR classification criteria - People who are currently receiving standard-dose rituximab and whose rheumatologist considers them to be responding well to it,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06946199 · Union Hospital, Tongji Medical College, Huazhong University of Science... Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old at the time of signing the consent form - People who have been diagnosed with adult-onset rheumatoid arthritis (RA), based on a specific set of recognised classification guidelines from 2010 - People whose RA is considered moderately to severely...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06947746 · Shanghai Changzheng Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to give written consent to participate in the study - People aged 18 to 65 years old (inclusive) at the time of signing the consent form - People who have been diagnosed with rheumatoid arthritis (RA) for at least 3 months, using recognised in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06955481 · Aesculap AG Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇨🇿 CZ🇩🇪 DE

Who might be able to join this trial: - People who have been assessed as needing a total knee replacement surgery using a specific system called the OrthoPilot® Navigation System with an Aesculap knee prosthesis - People who are willing and able to sign a consent form agreeing to take part in the study - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06965322 · Medical University Innsbruck Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2028
🇦🇹 AT

Who might be able to join this trial: - People aged 18 or older who have been diagnosed with rheumatoid arthritis according to recognised international guidelines - People who currently live in Austria - People who have signed and dated a consent form agreeing to take part in the study Who may not be able to join: - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06972446 · AbbVie Phase 2 · 13 countries Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇨🇦 CA🇨🇿 CZ🇩🇪 DE🇭🇺 HU🇵🇱 PL Puerto Rico🇷🇸 RS🇸🇰 SK +5 more

**Who might be able to join this trial:** - People who have been treated with at least one biologic or targeted synthetic DMARD (a type of specialist arthritis medication) for 3 months or more at some point before the screening visit, and whose rheumatoid arthritis remained active during that time — or who had to stop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06977035 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 November 2025
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with Rheumatoid Arthritis (RA) according to standard international classification guidelines (the 2010 ACR/EULAR criteria). - People who are 18 years of age or older. - People who are able to cooperate and respond to questions during the study. Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06994143 · Cullinan Therapeutics Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 30 December 2027
🇩🇪 DE🇮🇹 IT

**Who might be able to join this trial:** - People who have been formally diagnosed with rheumatoid arthritis (RA) for at least 12 weeks before the screening visit, based on recognised international criteria. - People whose RA appears to be driven by a part of the immune system called B-cells, shown either by certain...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06998628 · Tanta University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 May 2026
🇪🇬 EG

Who might be able to join this trial: - People who have active rheumatoid arthritis that is not currently in remission, confirmed by a standard joint activity score (called DAS28) above 2.6. - People who are currently being treated with conventional disease-modifying antirheumatic drugs (a standard class of medication...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07001956 · Union Hospital, Tongji Medical College, Huazhong University of Science... Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People with an expected survival time of at least 3 months - People with moderate-to-severe active rheumatoid arthritis that has not responded to standard treatments, or where no effective treatment options are available - People whose...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07013110 · Prof Salvatore Albani Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2028
🇸🇬 SG

Who might be able to join this trial: - People who have been diagnosed with rheumatoid arthritis (RA) according to a standard set of medical classification guidelines - People whose RA is at least moderately active, based on a disease activity score measured by a doctor - People aged 21 or older, of any gender - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07034196 · St. Lawrence Health System Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with rheumatoid arthritis (RA) according to a standard medical scoring system that looks at which joints are affected, certain blood test results, signs of inflammation, and how long symptoms have lasted (a score of at least 6 out of 10 is requ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07040930 · Changchun GeneScience Pharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 5 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 55 years, with at least 3 participants of each gender required per group - People with a BMI between 18 and 30, and a body weight of at least 50 kg for men or at least 45 kg for women - People with no significant health problems found during medical history...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07045896 · Peking University People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 65 years old (inclusive) at the screening stage, of any gender, who weigh at least 35 kg. - People who have been diagnosed with rheumatoid arthritis according to recognised 2010 classification standards. - People whose rheumatoid arthritis is currently...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07048197 · Novartis Pharmaceuticals Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 1 November 2028
🇫🇷 FR🇩🇪 DE🇸🇬 SG🇪🇸 ES

**Who might be able to join this trial:** - You must be willing and able to sign a consent form before taking part in the study - You must be between 18 and 75 years old at the time of your initial screening appointment - *(For Rheumatoid Arthritis patients)* You have been diagnosed with rheumatoid arthritis, your con...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07062523 · Peking Union Medical College Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2025
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 80 years old - People who have been diagnosed with primary Sjögren's syndrome (a condition that affects the immune system, often causing dry eyes and dry mouth) according to recognised 2016 classification guidelines, OR people who have been diagnosed wi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07089381 · Ain Shams University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇪🇬 EG

**Who might be able to join this trial:** - Adults aged 18 years or older. - People who have been formally diagnosed with rheumatoid arthritis (RA) using a recognised set of international medical guidelines (ACR/EULAR 2010 criteria). - People whose RA is currently rated as moderate to high in activity, based on a spec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07100873 · Adicet Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 March 2027
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with rheumatoid arthritis according to a recognised set of medical classification standards (the 2010 ACR-EULAR criteria — confirm with trial site if unsure whether this applies) - People who agree not to ta...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07123038 · Sonoma Biotherapeutics, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2040
🇺🇸 US

Who might be able to join this trial: - People who have previously received at least one dose of a Sonoma Biotherapeutics gene-modified Treg therapy as part of an earlier related treatment study. - People who understand what the study involves and its risks, and are willing to sign a written consent form. - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07126431 · Peking University Third Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with rheumatoid arthritis (RA) according to recognised medical guidelines (either from 1987 or 2010 standards) - You are older than 18 years of age - You have been taking standard disease-modifying medications (DMARDs) for at least 1 year - Your rheumatoid...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07137598 · Hoffmann-La Roche Phase 2 · 11 countries Recruiting
Recruiting Phase 2 Est. completion 19 April 2027
🇦🇷 AR🇧🇪 BE🇧🇷 BR🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇵🇱 PL +3 more

**Who might be able to join this trial:** - People who have moderate to severe active rheumatoid arthritis (RA), with at least 6 swollen joints and at least 6 tender joints measured at two separate check-in appointments. - People who have had a formal diagnosis of RA for at least 3 months, and whose diagnosis meets th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07138729 · Luo Yaping Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with rheumatoid arthritis according to the 2010 American College of Rheumatology/European Union for Rheumatology classification criteria - You have a high level of disease activity, measured by a clinical scoring s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07163221 · SecondWave Systems Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People with active moderate to severe rheumatoid arthritis that has tested positive for certain antibodies (seropositive RA) - People who have at least 6 tender and/or swollen joints out of 28 joints checked during the screening process (a joint tha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07171983 · Bristol-Myers Squibb Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 28 June 2027
🇮🇳 IN

Who might be able to join this trial: - You must have been diagnosed with Rheumatoid Arthritis (RA) that started after you turned 18 years old. - You must meet a specific set of recognized medical guidelines used to confirm a diagnosis of Rheumatoid Arthritis (confirm with trial site). - You must have at least one visi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07182656 · Yi Fang Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 April 2026
🇨🇳 CN

Who might be able to join this trial: - People who are generally healthy men or women between 18 and 45 years old (inclusive). - Men who weigh at least 50 kg and women who weigh at least 45 kg, with a body mass index (BMI) between 19.0 and 26.0 (a measure of weight relative to height). - People who are able to communic...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07222696 · Weill Medical College of Cornell University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older (male or female) - People who have been diagnosed with Rheumatoid Arthritis by a specialist doctor (rheumatologist) and are currently taking medication to manage the disease (either a standard or biological type of disease-modifying drug) - People who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07230353 · Xencor, Inc. Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 1 June 2028
🇬🇪 GE Moldova🇳🇿 NZ

Who might be able to join this trial: - Adults who have been diagnosed with rheumatoid arthritis (RA) that is moderately to severely active - People who received a confirmed RA diagnosis at least 3 months before the screening visit, meeting recognised classification standards for RA - People whose current RA treatments...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07245732 · Sunnybrook Health Sciences Centre Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 March 2029
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with rheumatoid arthritis, confirmed by a rheumatologist. - People who are taking anti-inflammatory medications (such as ibuprofen or naproxen) at a steady, unchanged dose for at least 2 weeks before joining the trial. - People who have been taking...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07258849 · Eli Lilly and Company Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 March 2028
🇩🇪 DE🇺🇸 US

Who might be able to join this trial: - People with a body mass index (BMI) between 18.0 and 32.0 (a measure of body weight relative to height), inclusive — this applies to certain parts of the trial only - People taking part in Parts C and D of the trial must weigh at least 50 kilograms and have a BMI between 18.0 and...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07264101 · Inonu University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2026
Turkey (Türkiye)

**Who might be able to join this trial:** - People aged between 18 and 65 years - People who have been diagnosed with rheumatoid arthritis based on the ACR/EULAR 2010 criteria - People whose treatment plan has not changed significantly (such as starting or adjusting disease-modifying or biologic medications, or a large...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07268326 · Center for Clinical Research and Prevention Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇩🇰 DK

Who might be able to join this trial: - Adults aged 18 or older - People with a rheumatoid arthritis disease activity score (DAS28) of 3.2 or below, with no swollen joints at the time of joining - People who have been diagnosed with rheumatoid arthritis for at least one year - People whose medication for rheumatoid art...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07281456 · National Institute of Dental and Craniofacial Research (NIDCR) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 December 2030
🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a written consent form - People who are enrolled in a related companion study (protocol 15-D-0051) about diseases involving the salivary glands - People who are willing to follow all study procedures and are...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07293871 · Surf Therapeutics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are at least 18 years old - People who have been diagnosed with rheumatoid arthritis (RA) according to established 2010 classification guidelines - People whose RA is at least moderately active, meaning they have 4 or more tender joints, 4 or more swollen joints,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07304505 · Ancilia Biosciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are able to give written consent to participate - People who are 18 years of age or older - People who have been clinically diagnosed with rheumatoid arthritis (RA) for more than 6 months - People who have been on a stable RA treatment plan for at least 3 months an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07315997 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 March 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with rheumatoid arthritis by a rheumatology specialist - People between the ages of 40 and 79 - People who have at least one heart disease risk factor, such as prediabetes, high blood pressure, a body mass index (BMI) over 30, or a current or past h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07320846 · Saglik Bilimleri Universitesi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
Turkey (Türkiye)

**Who might be able to join this trial:** - You have been diagnosed with rheumatoid arthritis (a condition where the immune system attacks the joints) based on recognised medical guidelines - You have had this diagnosis for more than 2 years - Your rheumatoid arthritis is moderately active, based on a specific disease...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07321340 · Centre Hospitalier Universitaire de Saint Etienne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with rheumatoid arthritis based on recognised medical guidelines (the 2010 ACR/EULAR criteria) - Your rheumatoid arthritis is currently at a low level of activity, based on a specific scoring system called DAS28 (confirm with trial site) - You have pain or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07347860 · Union Hospital, Tongji Medical College, Huazhong University of Science... Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old (any gender) - You have been diagnosed with rheumatoid arthritis (RA) for at least 24 weeks, based on recognized medical guidelines - You have tried at least one standard RA medication (called a csDMARD) in the past, and then also tried at...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07371468 · GlaxoSmithKline Phase 1 · 9 countries Recruiting
Recruiting Phase 1 Est. completion 15 March 2028
🇦🇷 AR🇧🇷 BR🇫🇷 FR🇮🇹 IT🇯🇵 JP Panama🇵🇱 PL🇪🇸 ES +1 more

**Who might be able to join this trial:** - People aged 18 to 70 years old at the time of signing the consent form. - People diagnosed with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) — for the first part of the trial. - People diagnosed with SLE, RA, idiopathic inflammatory myopathies (a type of m...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07381296 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇪🇬 EG

Who might be able to join this trial: - People who are older than 18 years of age. - People with a diagnosis of rheumatoid arthritis, confirmed using the 2010 international classification criteria for this condition. - People whose rheumatoid arthritis is currently in remission or showing low disease activity, as measu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07388407 · Foundation University Islamabad Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇵🇰 PK

Who might be able to join this trial: - People who have been diagnosed with rheumatoid arthritis based on the officially recognised international classification criteria (revised ACR/EULAR criteria) - People of Pakistani origin - People between the ages of 20 and 75 years old - People who have recently been started on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07401732 · Tanta University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with Rheumatoid Arthritis according to the 2010 international classification standards set by the American College of Rheumatology and the European League Against Rheumatism. - People who are over 18 years old, mentally alert, and able to cooperate...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07404865 · Vor Biopharma Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 75 years old (inclusive) - You have been diagnosed with primary Sjögren's Syndrome according to recognised international guidelines (from 2016) - Your Sjögren's Syndrome is considered active enough to meet a minimum disease activity score of 5 on a specific...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07408024 · Toll Biotech Co. Ltd. (Beijing) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 70 years old at the time of signing the consent form, of any gender - People who have been diagnosed with rheumatoid arthritis (RA) according to recognised medical classification systems - People whose RA disease activity score (a measure of joint inflammation a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07409103 · Elevara Medicines Limited Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 15 April 2027
🇿🇦 ZA🇺🇸 US

**Who might be able to join this trial:** - People who have given written agreement to take part and are willing to follow the study requirements. - People aged 18 to 75 years old at the time of signing the consent form. - People with a body weight of at least 50 kg and a body mass index (a measure of body weight rela...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07423533 · Changchun GeneScience Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to give their written agreement to take part, understand what the study involves, and commit to following the study procedures throughout. - People aged 18 to 70 years (inclusive) at the time of signing the consent form. - People who have been diagnose...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07433335 · SciRhom GmbH Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 29 February 2028
🇬🇪 GE Moldova🇷🇴 RO

**Who might be able to join this trial:** - People who are able to give written agreement to take part in the study - Men and women between 18 and 60 years of age (inclusive) - People who weigh at least 45 kg and have a body mass index (a measure of body weight relative to height) of 32 or below - People who have been...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07438652 · Kasr El Aini Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2026
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with rheumatoid arthritis based on the 2010 international classification criteria, and who are between 40 and 60 years old. Who may not be able to join: - People who have other health conditions alongside their rheumatoid arthritis, such as diabete...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07442773 · Glostrup University Hospital, Copenhagen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇩🇰 DK

Who might be able to join this trial: **For unpaid caregivers:** - You are an unpaid (informal) caregiver for an older adult who has been diagnosed with rheumatoid arthritis (a condition causing joint inflammation and pain) - You are 18 years of age or older - The person you care for is 65 years of age or older - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07463937 · Peking University People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults who have been diagnosed with rheumatoid arthritis based on recognised medical classification standards - People who, after being assessed by their doctor, are about to start or are planning to start methotrexate treatment given by injection under the skin, where the e...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07469540 · Jérôme Bouchan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with either Chronic Kidney Disease (CKD) or Rheumatoid Arthritis (RA), with no other risk factors linked to their condition. - People with CKD whose kidneys are functioning at a specific reduced level (stages III or IV of the disease) and who a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07473154 · Quell Therapeutics Limited Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2028
🇬🇧 GB

**Who might be able to join this trial:** - You must be 18 years old or older when you sign the consent form - Your vaccinations must be up to date, and you must not be planning to have any vaccines in the 3 months after your infusion - Your blood counts, liver, and kidneys must be working well enough (as confirmed by...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07491016 · Zhejiang Provincial People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 85 years old - You have been diagnosed with rheumatoid arthritis that has not responded to treatment, based on specific 2021 guidelines - You have already tried standard rheumatoid arthritis medications that did not work, and then tried two or more biol...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07516769 · Tanta University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2027
🇪🇬 EG

**Who might be able to join this trial:** - People who have active rheumatoid arthritis that is not currently in remission, confirmed by a standard disease activity score (called DAS-28) above 2.6 - People who are currently being treated with conventional disease-modifying anti-rheumatic drugs (DMARDs), which are a sta...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07517250 · Novartis Pharmaceuticals Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 December 2026
🇨🇭 CH

Who might be able to join this trial: - People (children or adults) who were prescribed the medication canakinumab before October 2021 and took it for at least 6 months to treat a condition called FMF (Familial Mediterranean Fever) or Still's disease (which includes two forms known as SJIA and AOSD). - People for whom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07524244 · Fuller Research Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have a medically confirmed diagnosis of Inflammatory Bowel Disease (IBD) or Rheumatoid Arthritis (RA) - People who currently live in the continental United States - People who are willing and able to follow specific dietary plans as part of the study **Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07533955 · Jade Biosciences, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 October 2027
Moldova🇺🇦 UA

**Who might be able to join this trial:** - You are between 18 and 70 years old (inclusive) - You weigh between 50 and 100 kg, and your body mass index (BMI) is between 18 and 32 (a measure of weight relative to height — confirm with trial site if unsure) - You have been officially diagnosed with Rheumatoid Arthritis (...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07554820 · Shaikh Zayed Hospital, Lahore Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 August 2026
🇵🇰 PK

Who might be able to join this trial: - People who have been diagnosed with rheumatoid arthritis that is moderately to severely active, even after trying more than 2 standard arthritis medications - People who have one or more risk factors for heart disease, such as high blood pressure, diabetes, smoking, or high chole...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07566351 · Horus University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇪🇬 EG

**Who might be able to join this trial:** - People who have been diagnosed with active rheumatoid arthritis based on recognised 2010 international classification standards - People whose joint disease activity score (measured across 28 joints) is above 2.6, indicating the condition is not well controlled - People aged...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07571993 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 June 2047
🇮🇹 IT

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with rheumatoid arthritis (RA) according to recognised medical classification guidelines, within 12 months of their first visit to an Early Arthritis Clinic - People who started conventional arthritis medication (known as c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07620392 · Hoffmann-La Roche Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 8 July 2033
🇺🇸 US

Who might be able to join this trial: - People who have finished the full treatment period of the related previous study (called the "parent study") - People who agree to follow the birth control requirements set out by the trial - People who attended their follow-up visit in the parent study and showed improvement in...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07632846 · Horus University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with active rheumatoid arthritis based on recognised international classification guidelines from 2010. - People whose disease activity score across 28 joints (a standard measurement of rheumatoid arthritis severity) is above 2.6, indicating active...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07632872 · Horus University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with active rheumatoid arthritis based on recognised classification standards set in 2010. - People whose disease activity score across 28 joints (a standard measurement of rheumatoid arthritis severity) is above 2.6, indicating the condition is not...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07646262 · Hasan Kalyoncu University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
Turkey (Türkiye)

**Who might be able to join this trial:** - People who have been diagnosed with rheumatoid arthritis based on recognised international criteria (ACR/EULAR) - People aged between 19 and 65 years - People whose arthritis medications have remained unchanged for at least 3 months before joining the trial - People who are w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07660029 · University of Ulster Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with rheumatoid arthritis and attend community groups or charity groups related to rheumatoid arthritis - People aged 18 years or older - People who can understand written and spoken English - People who are able to make their own decision about...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07674134 · Centre Hospitalier Princesse Grace Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
Monaco

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with Rheumatoid Arthritis based on the 2010 international diagnostic criteria - People whose condition meets the medical requirements for starting a type of medication called a JAK inhibitor, based on approved guideli...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07678034 · TIPMED Medical Device Manufacturing Ltd. Co. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2030
Turkey (Türkiye)

Who might be able to join this trial: - People who are 18 years of age or older - Both men and women are eligible to participate - People who have had a type of shoulder replacement surgery called Reverse Shoulder Arthroplasty or Shoulder Hemiarthroplasty, for any medically accepted reason - People whose shoulder repla...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07678112 · Francisco J. Blanco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇪🇸 ES

Who might be able to join this trial: - You must be 18 years old or older. - You must have been diagnosed with rheumatoid arthritis using recognised medical guidelines (from 1987 or 2010). - Your rheumatoid arthritis must have been in remission (very low disease activity) for at least 6 months before the study starts,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07704580 · Sanofi Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 26 October 2028
🇺🇸 US

Who might be able to join this trial: - People who are 18 years old or older (or the legal age of consent in the country where the study is taking place) at the time of signing the consent form. - People who have been diagnosed with rheumatoid arthritis (RA) according to recognised international classification standard...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07721142 · Shanghai Guanghua Hospital of Integrated Traditional Chinese and Weste... Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 15 March 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who fully understand the trial, are willing to sign a consent form, and are able to complete all required visits and procedures - Men aged 50 or older who do not wish to have children, or women who have gone through menopause, where all participants are under 70 years...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Rheumatoid Arthritis. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Arthritis Australia is the national body for rheumatoid arthritis and the other forms of arthritis it covers.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.